Bio-Rad (NYSE: BIO) hosts Droplet Digital PCR investor webinar replay

Rhea-AI Filing Summary

Bio-Rad Laboratories, Inc. filed a report describing an informational investor webinar focused on its Droplet Digital™ PCR (ddPCR™) product portfolio held on August 26, 2025. The webinar included a presentation and Q&A session with President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju. A live webcast and a replay, along with the slide presentation, are or will be available for up to a year in the Investor Relations section of the company’s website under “Events & Presentations.” The slide deck for the webinar is also provided as Exhibit 99.1, with the disclosure treated as furnished under Regulation FD rather than filed for liability purposes.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000012208false00000122082025-08-262025-08-260000012208us-gaap:CommonClassAMember2025-08-262025-08-260000012208us-gaap:CommonClassBMember2025-08-262025-08-26

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report:   August 26, 2025

(Date of earliest event reported)

BIO-RAD LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 1-07928

Delaware						94-1381833
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

1000 Alfred Nobel Dr.

Hercules, California 94547

(Address of principal executive offices, including zip code)

(510)724-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, Par Value $0.0001 per share

BIO

New York Stock Exchange

Class B Common Stock, Par Value $0.0001 per share

BIO.B

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

			Emerging growth company			☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.						☐

Item 7.01 Regulation FD Disclosure.

As previously announced, Bio-Rad Laboratories, Inc. (the “Company”) plans to host an informational webinar on Bio-Rad’s Droplet Digital™ PCR (ddPCR™) product portfolio on Tuesday, August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time). The event will include a presentation followed by a Q&A session with analysts hosted by the Company’s President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju.

A live webcast of the event will be available in the "Investor Relations" section of the Company’s website under "Events & Presentations" at investors.bio-rad.com. On August 26, 2025, the Company posted the informational webinar’s accompanying slide presentation on the “Investor Relations” section of its website under "Events & Presentations" at investors.bio-rad.com. A replay of the webcast and the accompanying slide presentation will be available for up to a year. A copy of the informational webinar’s accompanying slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Droplet Digital™ PCR Presentation dated August 26, 2025
104.1						Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIO-RAD LABORATORIES, INC.

Date:

August 26, 2025

By:

/s/ Courtney C. Enloe

Courtney C. Enloe

Executive Vice President, General Counsel & Secretary

FAQ

What did Bio-Rad (BIO) disclose in this 8-K filing?

Bio-Rad Laboratories disclosed that it is holding an informational investor webinar on its Droplet Digital™ PCR (ddPCR™) product portfolio, with a presentation and Q&A session hosted by senior executives, and that the related slide presentation is available as Exhibit 99.1 and on its Investor Relations website.

When is Bio-Rad's Droplet Digital PCR investor webinar taking place?

The informational webinar on Bio-Rad’s Droplet Digital™ PCR (ddPCR™) product portfolio is scheduled for August 26, 2025, at 10:00 AM Pacific Time (1:00 PM Eastern Time).

Where can investors access Bio-Rad (BIO) ddPCR webinar materials?

Investors can access a live webcast, replay, and the accompanying slide presentation for the ddPCR™ webinar in the “Investor Relations” section of Bio-Rad’s website under “Events & Presentations,” and the slide deck is also attached as Exhibit 99.1.

Which Bio-Rad executives are participating in the ddPCR investor webinar?

The webinar presentation and Q&A are hosted by Bio-Rad’s President and Chief Operating Officer Jon DiVincenzo and Chief Financial Officer Roop K. Lakkaraju.

How long will the Bio-Rad ddPCR webinar replay be available?

The replay of the webcast and the accompanying slide presentation will be available on Bio-Rad’s Investor Relations website for up to a year.

Is the Bio-Rad ddPCR webinar information considered filed with the SEC?

The information under Item 7.01 is furnished under Regulation FD and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or incorporated by reference into other filings, except if specifically referenced.